Where Are We with Cardiac Amyloidosis - Education Partner Program - OnDemand-Where Are We with Cardiac Amyloidosis

Where Are We with Cardiac Amyloidosis - Presentations

Pdf Summary

The document outlines the agenda and details for a medical educational event focused on Transthyretin Amyloidosis (ATTR), led by prominent medical experts. The event is designed for healthcare professionals, including physicians, nurses, nurse practitioners, physician assistants, and pharmacists. The sessions address the latest best practices in diagnosing and treating ATTR, including novel diagnostic techniques and emerging therapies.<br /><br />Key sessions include: <br />1. "ATTR Diagnosis: Current Best Practices and Emerging Horizons" by Dr. Justin Grodin, covering pathophysiology and diagnostic strategies for ATTR.<br />2. "Breaking Ground: The Latest Data and Game-Changing Therapies in ATTR" by Dr. Kevin Alexander, discussing new therapeutic options and clinical trial data for ATTR.<br />3. "ATTR in Focus: Engaging Case Vignettes and Real-World Insights" by Amy Brownell, offering practical insights through case studies.<br /><br />The event's learning objectives emphasize understanding current diagnostic and treatment practices for ATTR-related cardiomyopathy, evaluating new therapies, and discussing RNAi therapies' roles.<br /><br />Accreditation details state that physicians can earn up to 1.50 AMA PRA Category 1 Credits, with equivalent credits available for nurses, pharmacists, and physician assistants through the Heart Failure Society of America.<br /><br />Participants are informed about how to claim continuing education (CE) credit post-event by completing evaluations online. The document also provides off-label disclosure, advising participants to consult product information before applying the knowledge clinically. Faculty disclosures include affiliations and consultancies with various pharmaceutical companies.<br /><br />The event includes pre-test questions focused on identifying disease mechanisms and diagnostic accuracy for ATTR. The document concludes with further examination of advanced diagnostic possibilities like PET/SPECT-based tracers, blood biomarkers, ECG-based AI tools, and outlines promising trials and therapies, including gene-editing and anti-amyloid antibodies.

Keywords

Transthyretin Amyloidosis

medical educational event

healthcare professionals

diagnostic techniques

emerging therapies

ATTR cardiomyopathy

continuing education

RNAi therapies

clinical trials

gene-editing